Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 43

recruiting
3 987
countries
28
conditions
2 109

775 trials match your criteria

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Ribociclib and Letrozole for Patients with High-Risk Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Letrozole

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate

Acute myeloid leukaemia

Not recruiting

Study of Ivosidenib and Azacitidine for Patients Aged 18 and Older with Untreated Acute Myeloid Leukemia with IDH1 Mutation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Myelofibrosis+1

Not recruiting

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Danazol

Ovarian low malignant potential tumour

Not recruiting

Study of catequentinib (AL3818) combined with platinum chemotherapy for patients with recurrent or metastatic ovarian, fallopian tube, or primary peritoneal cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Catequentinib Dihydrochloride

Ductal adenocarcinoma of pancreas

Not recruiting

Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine

Plasma cell myeloma

Not recruiting

Study on Iberdomide and Dexamethasone, Alone or with Drug Combination, for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Moderate-to-Severe Atopic Hand Eczema in Patients Needing Systemic Therapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tralokinumab

Crohn's disease

Not recruiting

Study on the Effects of Ozanimod for Children with Moderate to Severe Crohn's Disease Not Responding to Usual Treatments

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Ozanimod

Pemphigoid

Not recruiting

Study on Efgartigimod Alfa and Prednisone for Adults with Bullous Pemphigoid

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin

Diffuse large B-cell lymphoma refractory+1

Not recruiting

Study on the Safety and Tolerability of Epcoritamab with Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Cyclophosphamide

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.